

Best Available Copy



Docket No.: CBR 3.0-017 CONT
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| | |
|------------------------------------|----------------------------|
| In re Patent Application of: | : |
| Moo-Young et al. | : |
| | : |
| Application No.: 10/736,428 | : |
| | : |
| Filed: December 15, 2003 | : Art Unit: 1617 |
| | : |
| For: TRANSDERMAL ADMINISTRATION OF | : Examiner: Kevin J. Capps |
| MENT | : |

DECLARATION UNDER 37 CFR 1.131

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

1. I, Yun-Yen Tsong, am one of the co-inventors with Alfred J. Moo-Young of the above-identified pending U.S. Patent Application No. 10/736,428, filed in the U.S. Patent and Trademark Office on December 15, 2003, which is a continuation of U.S. Patent Application No. 09/154,287, filed in the U.S. Patent and Trademark Office on September 16, 1998, which claimed the benefit of U.S. Provisional Patent Application No. 60/059,301, filed in the U.S. Patent and Trademark Office on September 13, 1997.

2. I am presently employed by The Population Council, Inc., the assignee of Application No. 10/736,428, and have been employed by The Population Council, Inc. for the last 36 years.

3. I invented the subject matter of Application No. 10/736,438, including that of claim 1 therein with

Dr. Moo-Young, and in accordance with our invention we reduced the invention to practice prior to August 21, 1997.

4. I am familiar with the prosecution of this patent application, as well as its parent applications, including official actions dated October 25, 2005 and June 29, 2006, in Application No. 10/736,428. In particular, the official actions dated October 25, 2005, and June 19, 2006, include a rejection based, at least in part, upon International Publication No. WO 97/29735 ("the '735 publication").

5. It is my understanding that the '735 publication was published on August 21, 1997, just more than one month prior to the effective filing date of our application in the U.S. Patent and Trademark Office.

6. Dr. Moo-Young and I completed the invention of claim 1 of the pending application in the United States before the date of publication of the '735 publication; namely, before August 21, 1997, claim 1 reading as follows:

1. A transdermal dosage form comprising: a non-5 α -reducible, 7 α -modified androgen comprising 7 α -methyl-19-nortestosterone and its pharmaceutically acceptable salts in a therapeutically effective amount, said androgen being dispersed within a pharmaceutically acceptable transdermal carrier, whereby said transdermal dosage form has a flux which is greater than that of testosterone in a similar formulation, said therapeutically effective amount comprising an amount of said non-5 α -reducible, 7 α -modified androgen sufficient to deliver between about 400 to about 1,600 micrograms of said androgen in bioavailable form over a 24-hour period.

7. In particular, prior to August 21, 1997, we were involved in the preparation of a transdermal drug delivery system for use in connection with certain non-5 α -reducible, 7 α -modified androgens, such as 7 α -methyl-19-nortestosterone

(MENT), and their application in a system which could be adhesively applied to the skin.

8. Prior to August 21, 1997, we thus invented and actually reduced to practice a transdermal delivery system for MENT which used MENT as a transdermal gel and which demonstrated that MENT had a flux which was greater than that of testosterone in a similar formulation, and which was able to deliver between about 400 to about 1600 micrograms of MENT in bioavailable form over a 24-hour period.

9. Attached hereto as Exhibit A is a seven-page document comprising the prepared handout for a meeting which took place prior to August 21, 1997, with the actual date thereof blanked out. This document includes a Table of Contents for that meeting and specific documents confirming specific testing which had been carried out and reported results therefrom.

10. The bioavailability of transdermal MENT gel formulations (2 mg MENT/g gel) were studied in rabbits. Under my direct supervision and control, three New Zealand white rabbits weighing 3.5 to 4.5 kg were used in each group. To each animal, either 0.2 grams of gel (0.4 mg of MENT) or 0.4 grams of gel (0.8 mg of MENT) was applied to 5X5 cm areas of shaved skin daily for both groups of rabbits for three days. Blood samples were taken on days 1 and 3 at 0, 1, 2, 4, 8, and 24 hours after application of the gel. The amount of MENT in the blood was determined by radioimmunoassay, all of which is shown on page 4 of Exhibit A attached hereto, all of which was prepared prior to August 21, 1997. The results obtained are shown on pages 6 and 7 of Exhibit A, which correspond to FIGS. 15 and 14, respectively, in Patent Application No. 10/736,428.

11. The gel compositions themselves utilized a gel-based formulation which is set forth in Gel Formulation O in paragraph [0123] on page 37 of Patent Application No. 10/736,428, including 1.0 grams of methyl cellulose, 0.3 grams of carbopol, 0.90 grams of benzyl alcohol, 35.0 grams of propylene glycol, 10.0 grams of isopropyl alcohol, and the rest of the 100 gram composition as water.

12. The results of rat skin flux rate comparison between the use of 7 α -methyl-19-nortestosterone and testosterone is shown in FIG. 9 of Patent Application No. 10/736,428, demonstrating a much higher flux rate for the 7 α -methyl-19-nortestosterone than for the testosterone in the Gel Formulation O.

13. I have recently recalculated these results in terms of $\mu\text{g}/\text{cm}^2/\text{hr}$ instead of $\mu\text{g}/\text{ml}$, as shown in the figure on page 5 of Exhibit A, and these results are shown in the figure which is attached hereto as Exhibit B.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may

Application No.: 10/736,428

Docket No.: CBR 3.0-017 CONT

jeopardize the validity of the application or any patent issuing thereon.

Dated: August 29, 2006

By 

YUN-YEN TSONG, Ph.D.

645513_1

INTERNATIONAL COMMITTEE FOR CONTRACEPTION RESEARCH
New York, April 17-18, 1996
68th Meeting

Table of Contents

I. Subdermal Implants for Women

A. NORPLANT® and NORPLANT® II

Clinical Studies

a. Serum Level Data

| | |
|---------------------------|---|
| i. Mishell | 1 |
| ii. Massai/Croxatto | 6 |
| iii. Sivin | 7 |

b. Performance Data

| | |
|-------------|----|
| Sivin | 11 |
|-------------|----|

c. Other Studies

| | |
|-------------------|----|
| i. Massai | 15 |
| ii. Fraser | 17 |
| iii. Fraser | 18 |

B. Nestorone™ Implant

Clinical Studies

| | |
|----------------------|----|
| a. Byrne | 20 |
| b. Brache | 29 |
| c. Lähteenmäki | 33 |
| d. Massai | 41 |
| e. Croxatto | 46 |

II. Subdermal Implants for Men

A. Peptide Implant

Clinical Study

| | |
|-----------------|----|
| Moo-Young | 47 |
|-----------------|----|

B. MENT

Animal Studies

| | |
|----------------|----|
| Sundaram | 61 |
|----------------|----|

III. Intrauterine Devices (IUDs)

A. Levonorgestrel-Releasing IUD

Clinical Studies

| | |
|----------------|----|
| a. Maruo | 64 |
|----------------|----|

| | |
|---|-----|
| b. Aguiillaume | 70 |
| B. Levonorgestrel-Releasing ICD | |
| Clinical Study | |
| Lähteenmäki | 71 |
| IV. Immunocontraception | |
| GnRH | |
| Animal Studies | |
| Tsong | 75 |
| V. Contraceptive Rings | |
| A. Nestorone™ Ring | |
| Clinical Study | |
| Massai | 78 |
| B. Nestorone™ Progestin/Ethinylestradiol Ring | |
| <i>In vitro</i> Studies | |
| Jackanicz | 80 |
| C. Progesterone Ring | |
| Clinical Study | |
| Massai | 82 |
| D. Estradiol Ring | |
| Clinical Study | |
| Nash | 85 |
| E. Ethinylestradiol Burst | |
| Nash | 92 |
| VI. Probing Studies | |
| A. Microbicides | |
| Laboratory Studies | |
| Phillips | 95 |
| B. Mifepristone | |
| Clinical Study | |
| Croxatto | 97 |
| C. Misoprostol | |
| Clinical Study | |
| Aguiillaume | 98 |
| D. Anordiol | |
| Animal Studies | |
| a. Koide | 99 |
| b. Bagchi | 100 |
| E. Transdermal Delivery of MENT | |
| Animal Study | |
| Tsong | 101 |

VII. Special Reports

A. Effects of LHRH Analogs in Women

Bouchard 105

B. Mirena®: The Levonorgestrel Delivery System for the Uterus - Market Feedback from Europe

Johansson 106

Action Items 107


E. Transdermal Delivery of MENT

Animal Study

Dr. Tsong reported that MENT permeated rat skin when it was applied as a transdermal gel in the *in vitro* Franz cell study (Figure 1), though MENT acetate did not. Under the same study conditions, the rate of permeation of MENT is about three times that of Nestorone™ progestin. The bioavailability of MENT transdermal gel in rabbits was studied in collaboration with Dr. Sundaram's laboratory. Animals were divided into two groups, three rabbits per group. To one group of rabbits, 0.2 g of gel (0.4 mg MENT) was applied to a 5 x 5 cm area of shaved skin. The second group of rabbits received a double dose (0.8 mg) of MENT by applying 0.2 g of gel to each of two 5 x 5 cm patches of shaved skin. The gel was applied daily to both groups of rabbits for three days. Blood samples were taken on Days 1 and 3 at 0, 1, 2, 4, 8, and 24 hours after application of the gel. The amount of MENT in the blood was determined by radioimmunoassay. In both the high-dose (Figure 2) and low-dose (Figure 3) groups, serum levels of MENT reached a peak one hour after application of the gel on Day 1. On Day 3, MENT levels peaked two hours after application and were non-detectable after 8 hours. Calculation of the areas under the curves showed similar values for Days 1 and 3. The results indicated that transdermal delivery is a viable method of MENT administration.

Figure 1


MENT In Vitro Rat Skin Permeation



The *in vitro* rat skin permeation study of MENT transdermal gel. The gel contained 2 mg MENT per g gel

Figure 2


MENT Rabbit Skin Permeation
MENT Dosage: 0.8mg MENT/0.4mL gel



The bioavailability of MENT in rabbits after administration of 0.4 g of MENT transdermal gel (2 mg MENT per g gel) for three consecutive days.


Figure 3

MENT Rabbit Skin Permeation
MENT Dosage: 0.4mg MENT/0.2mL gel




The bioavailability of MENT in rabbits after administration of 0.2 g of MENT transdermal gel (2 mg MENT per g gel) for three consecutive days.

MENT In Vitro Rat Skin Permeation



MENT In Vitro Rat Skin Permeation



**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.